Since our establishment, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode.

?

With fully integrated bi-specific antibody drug development technology platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease, and other major therapeutic areas. Akeso has successfully promoted the commercialization of 5 innovative biological drugs (one out-licensed drug), 22 assets have entered clinical stage.

?

In June 2022, 开坦尼^??(PD-1/CTLA-4 bi-specific antibody, Cadonilimab injection) was approved by the NMPA and became the first tumor dual immune checkpoint inhibitor bi-specific antibody approved for marketing?globally. In May?2024, 依达方^??(PD-1/VEGF bi-specific antibody,Ivonescimab injection) , the first-in-class PD-1/VEGF?bi-specific antibody ?independently developed by the Company, has been granted marketing approval by the NMPA of China for the treatment of epidermal growth factor receptor (“EGFR”) mutated locally advanced or metastatic non-squamous non-small cell lung cancer (“nsq-NSCLC”) .?The?drug?had?been granted three Breakthrough Therapy Designations for the treatment of lung cancer?by the Center for Drug Evaluation (CDE)?.In December 2022, the Company out-licensed the antibody with up to US$5 Billion total potential deal value to Summit Therapeutics for development and commercialization in the U.S., Canada, Europe, and Japan. In September 2024，Akeso’s first non-oncology drug and the fifth product in the commercial portfolio 伊喜宁^?（PCSK9 Monoclonal antibody，Ebronucimab injection) has been approved by the NMPA in China ，for two indications of hypercholesterolemia.Another Akeso internally discovered and developed oncology product,安尼可^? (PD-1 monoclonal antibody, Penpulimab injection) , was granted marketing approval in China in August 2021.